Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Day One Biopharmaceuticals ( (DAWN) ) has provided an announcement.
Day One Biopharmaceuticals reported its third quarter 2025 financial results, highlighting a strong commercial performance of OJEMDA, with net product revenue reaching $38.5 million, a 15% increase from the previous quarter. The company raised its full-year 2025 net product revenue guidance to $145 to $150 million, reflecting strong demand. The company also announced progress in its clinical trials, including the Phase 3 FIREFLY-2 trial and the Phase 1a trial of DAY301, and noted the addition of tovorafenib to the NCCN treatment guidelines. Despite a net loss of $19.7 million for the quarter, Day One ended the period with $451.6 million in cash and investments, positioning it well for future growth.
The most recent analyst rating on (DAWN) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.
Spark’s Take on DAWN Stock
According to Spark, TipRanks’ AI Analyst, DAWN is a Neutral.
Day One Biopharmaceuticals shows strong growth potential, particularly with the success of OJEMDA and a solid cash position. However, consistent net losses, negative technical indicators, and a challenging valuation due to ongoing losses present significant risks. The strong momentum from recent earnings highlights provides some optimism, balancing out the weaker financial and technical aspects.
To see Spark’s full report on DAWN stock, click here.
More about Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biopharmaceutical company focused on developing and commercializing targeted therapies for patients of all ages with life-threatening diseases, particularly pediatric cancer. The company is based in Brisbane, California, and its pipeline includes tovorafenib (OJEMDA) and DAY301.
Average Trading Volume: 1,540,234
Technical Sentiment Signal: Hold
Current Market Cap: $748.8M
For a thorough assessment of DAWN stock, go to TipRanks’ Stock Analysis page.